George Angelidis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
George Angelidis has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Panagiotis Georgoulias
Department of Nuclear Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece
16 shared publications - Ioannis Tsougos
Medical Physics Department, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece
14 shared publications Varvara Valotassiou
Nuclear Medicine Laboratory, University of Thessaly, University Hospital of Larissa, Mezourlo, Larissa, 41110, Greece
12 shared publications- Dimitrios Psimadas
Nuclear Medicine Laboratory, University Hospital of Larissa, University of Thessaly, 41110 Larissa, Greece
11 shared publications Panagiotis Georgoulias
Nuclear Medicine Laboratory, University of Thessaly, University Hospital of Larissa, Mezourlo, Larissa, 41110, Greece
9 shared publications- Varvara Valotassiou
Nuclear Medicine Laboratory, University Hospital of Larissa, University of Thessaly, 41110 Larissa, Greece
7 shared publications
Latest Publications
- Open Access
- 10 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1796
Decoding the Myocardium: Tracer-Aware Deep Learning for Patient-Level Classification in Stress–Rest SPECT Myocardial Perfusion Imaging
Background/Objectives: Single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) is widely used for non-invasive assessment of coronary artery disease under stress and rest conditions. Although deep learning has shown promise for automated SPECT MPI interpretation, most studies focus on single-tracer datasets and do not explicitly account for tracer-dependent variability. This study developed and evaluated a multi-task deep learning framework with tracer-specific prediction heads for patient-level SPECT MPI classification. Methods: A convolutional neural network with a shared feature encoder and tracer-specific heads was implemented using polar map representations from technetium-99m (Tc-99m) and thallium-201 (Tl-201) studies. Transfer learning from ImageNet was applied. Stress-only, rest-only, and dual-input configurations were evaluated using repeated patient-stratified cross-validation and independent testing. Performance was assessed using ROC-AUC and balanced accuracy. Results: For Tc-99m normal versus abnormal perfusion classification, the stress-only model achieved the highest cross-validation AUC (0.88 ± 0.067) and test AUC of 0.88 [0.67–0.99]. For Tl-201 low-risk versus intermediate/high-risk classification, stress-based models achieved the highest cross-validation AUC (0.88 ± 0.051) and test AUC of 0.80 [0.71–0.89], comparable to dual-input models. In both tracer-specific tasks, stress-phase information showed favorable performance, but the endpoints differed and should be interpreted separately. Conclusions: Stress-phase polar maps provided strong discriminative information within this single-center cohort. These findings should be interpreted in a tracer- and task-specific manner supporting stress-phase imaging as an informative input for AI-based SPECT MPI classification while underscoring the need for external validation before broader clinical generalization.
- 10 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1796
Open AccessDecoding the Myocardium: Tracer-Aware Deep Learning for Patient-Level Classification in Stress–Rest SPECT Myocardial Perfusion Imaging
Background/Objectives: Single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) is widely used for non-invasive assessment of coronary artery disease under stress and rest conditions. Although deep learning has shown promise for automated SPECT MPI interpretation, most studies focus on single-tracer datasets and do not explicitly account for tracer-dependent variability. This study developed and evaluated a multi-task deep learning framework with tracer-specific prediction heads for patient-level SPECT MPI classification. Methods: A convolutional neural network with a shared feature encoder and tracer-specific heads was implemented using polar map representations from technetium-99m (Tc-99m) and thallium-201 (Tl-201) studies. Transfer learning from ImageNet was applied. Stress-only, rest-only, and dual-input configurations were evaluated using repeated patient-stratified cross-validation and independent testing. Performance was assessed using ROC-AUC and balanced accuracy. Results: For Tc-99m normal versus abnormal perfusion classification, the stress-only model achieved the highest cross-validation AUC (0.88 ± 0.067) and test AUC of 0.88 [0.67–0.99]. For Tl-201 low-risk versus intermediate/high-risk classification, stress-based models achieved the highest cross-validation AUC (0.88 ± 0.051) and test AUC of 0.80 [0.71–0.89], comparable to dual-input models. In both tracer-specific tasks, stress-phase information showed favorable performance, but the endpoints differed and should be interpreted separately. Conclusions: Stress-phase polar maps provided strong discriminative information within this single-center cohort. These findings should be interpreted in a tracer- and task-specific manner supporting stress-phase imaging as an informative input for AI-based SPECT MPI classification while underscoring the need for external validation before broader clinical generalization.
- Open Access
- 19 May 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (10) , 1542
Fibroblast Activation Protein Inhibitor (FAPI) PET: A Scoping Review of Emerging Oncologic and Fibroinflammatory Applications
This scoping review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines. It summarizes advances in fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET) for oncologic and fibroinflammatory diseases. FAP is expressed broadly on activated mesenchymal cells—including cancer-associated fibroblasts (CAFs) and myofibroblasts within desmoplastic tumor stroma, FAP-positive tumor cells in selected sarcomas, and activated fibroblasts in chronic fibroinflammatory disorders such as rheumatoid arthritis, Crohn’s disease, and organ fibrosis. By targeting these activated fibroblasts, [68Ga]- and [18F]-labeled FAPI tracers provide high tumor-to-background contrast, particularly in desmoplastic and stromal-rich cancers. Compared with [18F]FDG, FAPI PET demonstrates superior lesion conspicuity in selected malignancies and enables a streamlined, non-fasting imaging workflow. Beyond oncology, FAPI PET is emerging as a promising tool for assessing cardiac fibrosis, pulmonary inflammation, and autoimmune conditions characterized by fibroblast activation. A systematic literature search of PubMed and Scopus was performed for peer-reviewed publications from 1 January 2018 to 28 February 2026. Inclusion criteria encompassed original studies, systematic reviews, meta-analyses, clinical guidelines, case series, and case reports reporting on FAPI-targeted PET in human subjects or translational models, published in English. After screening, 256 sources met the eligibility criteria and are included. The development of standardized SNMMI/EANM imaging protocols, along with ongoing multicenter trials and the first prospective phase 2 clinical trial of 68Ga-FAPI-46 PET with histopathological confirmation, now supports the reproducible implementation of FAPI PET across institutions. FAPI PET demonstrates strong translational potential, largely due to its favorable biodistribution, safety profile, and theranostic flexibility. However, its widespread use in routine clinical practice is contingent upon large-scale clinical validation, structured reader training, and formal regulatory approval. In conclusion, FAPI PET represents a maturing molecular imaging platform targeting activated fibroblasts across oncologic and fibroinflammatory diseases. Its widespread adoption into clinical practice requires large-scale prospective trials, reader training, standardized reporting, and regulatory approval—all of which are now actively underway.
- 19 May 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (10) , 1542
Open AccessFibroblast Activation Protein Inhibitor (FAPI) PET: A Scoping Review of Emerging Oncologic and Fibroinflammatory Applications
This scoping review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines. It summarizes advances in fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET) for oncologic and fibroinflammatory diseases. FAP is expressed broadly on activated mesenchymal cells—including cancer-associated fibroblasts (CAFs) and myofibroblasts within desmoplastic tumor stroma, FAP-positive tumor cells in selected sarcomas, and activated fibroblasts in chronic fibroinflammatory disorders such as rheumatoid arthritis, Crohn’s disease, and organ fibrosis. By targeting these activated fibroblasts, [68Ga]- and [18F]-labeled FAPI tracers provide high tumor-to-background contrast, particularly in desmoplastic and stromal-rich cancers. Compared with [18F]FDG, FAPI PET demonstrates superior lesion conspicuity in selected malignancies and enables a streamlined, non-fasting imaging workflow. Beyond oncology, FAPI PET is emerging as a promising tool for assessing cardiac fibrosis, pulmonary inflammation, and autoimmune conditions characterized by fibroblast activation. A systematic literature search of PubMed and Scopus was performed for peer-reviewed publications from 1 January 2018 to 28 February 2026. Inclusion criteria encompassed original studies, systematic reviews, meta-analyses, clinical guidelines, case series, and case reports reporting on FAPI-targeted PET in human subjects or translational models, published in English. After screening, 256 sources met the eligibility criteria and are included. The development of standardized SNMMI/EANM imaging protocols, along with ongoing multicenter trials and the first prospective phase 2 clinical trial of 68Ga-FAPI-46 PET with histopathological confirmation, now supports the reproducible implementation of FAPI PET across institutions. FAPI PET demonstrates strong translational potential, largely due to its favorable biodistribution, safety profile, and theranostic flexibility. However, its widespread use in routine clinical practice is contingent upon large-scale clinical validation, structured reader training, and formal regulatory approval. In conclusion, FAPI PET represents a maturing molecular imaging platform targeting activated fibroblasts across oncologic and fibroinflammatory diseases. Its widespread adoption into clinical practice requires large-scale prospective trials, reader training, standardized reporting, and regulatory approval—all of which are now actively underway.
- Open Access
- 8 May 2026
- Published by Springer Nature in EJNMMI Reports
- Vol. 10 (1)
Combating radiophobia: a top priority for the further development of nuclear medicine
- 8 May 2026
- Published by Springer Nature in EJNMMI Reports
- Vol. 10 (1)
Open AccessCombating radiophobia: a top priority for the further development of nuclear medicine
- Open Access
- 1 January 2026
- Published by Tech Science Press in Canadian Journal of Urology
- p. 1-10
PSMA PET imaging in localized prostate cancer and biochemical recurrence: current evidence and clinical applications
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has emerged as a transformative imaging modality in the management of prostate cancer, particularly for patients with localized disease and those experiencing biochemical recurrence (BCR). This review focuses on the clinical applications of PSMA PET imaging in these two critical clinical scenarios, where accurate disease detection and localization directly impact treatment decisions. For patients with localized high-risk prostate cancer, PSMA PET provides superior staging accuracy compared to conventional imaging, detecting occult lymph node and distant metastases that may change the therapeutic approach from curative local treatment to systemic therapy. In the setting of BCR, PSMA PET demonstrates remarkable detection capabilities even at very low prostate-specific antigen (PSA) levels, enabling accurate localization of recurrent disease sites in patients with established BCR, and guiding appropriate salvage treatment strategies. The integration of PSMA PET findings with clinical and pathological parameters enhances risk stratification and supports personalized treatment planning. This review examines the biological basis of PSMA expression, the development and characteristics of key PSMA radiotracers, the diagnostic performance in initial staging and BCR detection, and the clinical impact on management decisions. Additionally, the role of quantitative imaging biomarkers, standardized reporting systems, and potential limitations of PSMA PET are discussed. The available evidence demonstrates that PSMA PET imaging has become an indispensable tool in the modern management of localized prostate cancer and BCR, with significant implications for treatment selection and patient outcomes.
- 1 January 2026
- Published by Tech Science Press in Canadian Journal of Urology
- p. 1-10
Open AccessPSMA PET imaging in localized prostate cancer and biochemical recurrence: current evidence and clinical applications
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has emerged as a transformative imaging modality in the management of prostate cancer, particularly for patients with localized disease and those experiencing biochemical recurrence (BCR). This review focuses on the clinical applications of PSMA PET imaging in these two critical clinical scenarios, where accurate disease detection and localization directly impact treatment decisions. For patients with localized high-risk prostate cancer, PSMA PET provides superior staging accuracy compared to conventional imaging, detecting occult lymph node and distant metastases that may change the therapeutic approach from curative local treatment to systemic therapy. In the setting of BCR, PSMA PET demonstrates remarkable detection capabilities even at very low prostate-specific antigen (PSA) levels, enabling accurate localization of recurrent disease sites in patients with established BCR, and guiding appropriate salvage treatment strategies. The integration of PSMA PET findings with clinical and pathological parameters enhances risk stratification and supports personalized treatment planning. This review examines the biological basis of PSMA expression, the development and characteristics of key PSMA radiotracers, the diagnostic performance in initial staging and BCR detection, and the clinical impact on management decisions. Additionally, the role of quantitative imaging biomarkers, standardized reporting systems, and potential limitations of PSMA PET are discussed. The available evidence demonstrates that PSMA PET imaging has become an indispensable tool in the modern management of localized prostate cancer and BCR, with significant implications for treatment selection and patient outcomes.
- Open Access
- 25 December 2025
- Published by MDPI AG in Journal of Imaging
- Vol. 12 (1) , 6
Long-Term Prognostic Value in Nuclear Cardiology: Expert Scoring Combined with Automated Measurements vs. Angiographic Score
The evaluation of myocardial perfusion imaging (MPI) studies is based on the visual interpretation of the reconstructed images, while the measurements obtained through software packages may contribute to the investigation, mainly in cases of ambiguous scintigraphic findings. We aimed to investigate the long-term prognostic value of expert reading of Summed Stress Score (SSS), Summed Rest Score (SRS), and Summed Difference Score (SDS), combined with the automated measurements of these parameters, in comparison to the prognostic ability of the angiographic score for soft and hard cardiac events. The study was conducted at the Nuclear Medicine Laboratory of the University of Thessaly, in Larissa, Greece. Overall, 378 consecutive patients with known or suspected coronary artery disease (CAD) were enrolled. Automated measurements of SSS, SRS, and SDS were obtained using the Emory Cardiac Toolbox, Myovation, and Quantitative Perfusion SPECT software packages. Coronary angiographies were scored according to a four-point scoring system (angiographic score). Follow-up data were recorded after phone contact, as well as through review of hospital records. All participants were followed up for at least 36 months. Soft and hard cardiac events were recorded in 31.7% and 11.6% of the sample, respectively, while any cardiac event was recorded in 36.5%. For hard cardiac events, the prognostic value of expert scoring, combined with the prognostic value of the automated measurements, was significantly greater compared to the prognostic ability of the angiographic score (p < 0.001). As far as any cardiac event, the prognostic value of expert scoring, combined with the prognostic value of the automated analyses, was significantly greater compared to the prognostic ability of the angiographic score (p < 0.001). According to our results, in patients with known or suspected CAD, the combination of expert reading and automated measurements of SSS, SRS, and SDS shows a superior prognostic ability in comparison to the angiographic score.
- 25 December 2025
- Published by MDPI AG in Journal of Imaging
- Vol. 12 (1) , 6
Open AccessLong-Term Prognostic Value in Nuclear Cardiology: Expert Scoring Combined with Automated Measurements vs. Angiographic Score
The evaluation of myocardial perfusion imaging (MPI) studies is based on the visual interpretation of the reconstructed images, while the measurements obtained through software packages may contribute to the investigation, mainly in cases of ambiguous scintigraphic findings. We aimed to investigate the long-term prognostic value of expert reading of Summed Stress Score (SSS), Summed Rest Score (SRS), and Summed Difference Score (SDS), combined with the automated measurements of these parameters, in comparison to the prognostic ability of the angiographic score for soft and hard cardiac events. The study was conducted at the Nuclear Medicine Laboratory of the University of Thessaly, in Larissa, Greece. Overall, 378 consecutive patients with known or suspected coronary artery disease (CAD) were enrolled. Automated measurements of SSS, SRS, and SDS were obtained using the Emory Cardiac Toolbox, Myovation, and Quantitative Perfusion SPECT software packages. Coronary angiographies were scored according to a four-point scoring system (angiographic score). Follow-up data were recorded after phone contact, as well as through review of hospital records. All participants were followed up for at least 36 months. Soft and hard cardiac events were recorded in 31.7% and 11.6% of the sample, respectively, while any cardiac event was recorded in 36.5%. For hard cardiac events, the prognostic value of expert scoring, combined with the prognostic value of the automated measurements, was significantly greater compared to the prognostic ability of the angiographic score (p < 0.001). As far as any cardiac event, the prognostic value of expert scoring, combined with the prognostic value of the automated analyses, was significantly greater compared to the prognostic ability of the angiographic score (p < 0.001). According to our results, in patients with known or suspected CAD, the combination of expert reading and automated measurements of SSS, SRS, and SDS shows a superior prognostic ability in comparison to the angiographic score.
- Open Access
- 23 October 2025
- Published by Frontiers Media SA in Frontiers in Nuclear Medicine
- Vol. 5, 1645497
PET/CT imaging of bone disorders in dysparathyroidism: a comprehensive review
Parathyroid disorders profoundly affect bone metabolism, often long before structural damage is apparent on conventional imaging. Positron emission tomography/computed tomography (PET/CT) has emerged as a transformative tool in dysparathyroidism, enabling visualization of early metabolic bone changes and accurate localization of parathyroid pathology. This review explores the pathophysiology of bone disease in hyper- and hypoparathyroidism and highlights the role of key PET radiotracers: fluorine-18 sodium fluoride ([18F]NaF), fluorine-18 fluorodeoxyglucose ([18F]FDG), fluorine-18 fluorocholine ([18F]FCH), gallium-68 prostate-specific membrane antigen ([68Ga]PSMA). Distinct imaging patterns, such as the [18F]NaF “superscan” in secondary hyperparathyroidism and focal uptake in brown tumors, are discussed alongside tracer-specific strengths. Clinical applications including diagnosis, monitoring response to therapy, and prognostication are examined. We also consider emerging technologies such as artificial intelligence (AI)-assisted interpretation and positron emission tomography/magnetic resonance imaging (PET/MRI) fusion imaging. As PET/CT becomes more accessible, it is likely to play an increasingly central role in the early detection and personalized management of parathyroid-related bone disease.
- 23 October 2025
- Published by Frontiers Media SA in Frontiers in Nuclear Medicine
- Vol. 5, 1645497
Open AccessPET/CT imaging of bone disorders in dysparathyroidism: a comprehensive review
Parathyroid disorders profoundly affect bone metabolism, often long before structural damage is apparent on conventional imaging. Positron emission tomography/computed tomography (PET/CT) has emerged as a transformative tool in dysparathyroidism, enabling visualization of early metabolic bone changes and accurate localization of parathyroid pathology. This review explores the pathophysiology of bone disease in hyper- and hypoparathyroidism and highlights the role of key PET radiotracers: fluorine-18 sodium fluoride ([18F]NaF), fluorine-18 fluorodeoxyglucose ([18F]FDG), fluorine-18 fluorocholine ([18F]FCH), gallium-68 prostate-specific membrane antigen ([68Ga]PSMA). Distinct imaging patterns, such as the [18F]NaF “superscan” in secondary hyperparathyroidism and focal uptake in brown tumors, are discussed alongside tracer-specific strengths. Clinical applications including diagnosis, monitoring response to therapy, and prognostication are examined. We also consider emerging technologies such as artificial intelligence (AI)-assisted interpretation and positron emission tomography/magnetic resonance imaging (PET/MRI) fusion imaging. As PET/CT becomes more accessible, it is likely to play an increasingly central role in the early detection and personalized management of parathyroid-related bone disease.
- Open Access
Long-Term Prognostic Value of Automated Measurements in Nuclear Cardiology: Comparisons with Expert Scoring
Background and Objectives: Automated methods for the analysis of myocardial perfusion studies have been incorporated into clinical practice, but they are currently used as adjuncts to the visual interpretation. We aimed to investigate the role of automated measurements of summed stress score (SSS), summed rest score (SRS), and summed difference score (SDS) as long-term prognostic markers of morbidity and mortality, in comparison to the prognostic value of expert reading. Materials and Methods: The study was conducted at the Nuclear Medicine Laboratory of the University of Thessaly, in Larissa, Greece. A total of 378 consecutive patients with known or suspected coronary artery disease were enrolled in the study. All participants were referred to our laboratory for the performance of stress/rest myocardial perfusion single photon emission computed tomography. Automated measurements of SSS, SRS, and SDS were obtained by Emory Cardiac Toolbox (ECTb (Version 3.0), Emory University, Atlanta, GA, USA), Myovation (MYO, Xeleris version 3.05, GE Healthcare, Chicago, IL, USA), and Quantitative Perfusion SPECT (QPS (Version 4.0), Cedars-Sinai Medical Center, Los Angeles, CA, USA) software packages. Follow-up data were recorded after phone contacts, as well as through review of hospital records. Results: Expert scoring of SSS and SDS had significantly greater prognostic ability in comparison to all software packages (p < 0.001 for all comparisons). Similarly, ECTb-obtained SRS measurements had significantly lower prognostic ability in comparison to expert scoring (p < 0.001), while expert scoring of SRS showed significantly higher prognostic ability compared to MYO (p = 0.018) and QPS (p < 0.001). Conclusions: Despite the useful contribution of automated analyses in the interpretation of myocardial perfusion studies, expert reading should continue to have a crucial role, not only in clinical decision making, but also in the assessment of prognosis.
Open AccessLong-Term Prognostic Value of Automated Measurements in Nuclear Cardiology: Comparisons with Expert Scoring
Background and Objectives: Automated methods for the analysis of myocardial perfusion studies have been incorporated into clinical practice, but they are currently used as adjuncts to the visual interpretation. We aimed to investigate the role of automated measurements of summed stress score (SSS), summed rest score (SRS), and summed difference score (SDS) as long-term prognostic markers of morbidity and mortality, in comparison to the prognostic value of expert reading. Materials and Methods: The study was conducted at the Nuclear Medicine Laboratory of the University of Thessaly, in Larissa, Greece. A total of 378 consecutive patients with known or suspected coronary artery disease were enrolled in the study. All participants were referred to our laboratory for the performance of stress/rest myocardial perfusion single photon emission computed tomography. Automated measurements of SSS, SRS, and SDS were obtained by Emory Cardiac Toolbox (ECTb (Version 3.0), Emory University, Atlanta, GA, USA), Myovation (MYO, Xeleris version 3.05, GE Healthcare, Chicago, IL, USA), and Quantitative Perfusion SPECT (QPS (Version 4.0), Cedars-Sinai Medical Center, Los Angeles, CA, USA) software packages. Follow-up data were recorded after phone contacts, as well as through review of hospital records. Results: Expert scoring of SSS and SDS had significantly greater prognostic ability in comparison to all software packages (p < 0.001 for all comparisons). Similarly, ECTb-obtained SRS measurements had significantly lower prognostic ability in comparison to expert scoring (p < 0.001), while expert scoring of SRS showed significantly higher prognostic ability compared to MYO (p = 0.018) and QPS (p < 0.001). Conclusions: Despite the useful contribution of automated analyses in the interpretation of myocardial perfusion studies, expert reading should continue to have a crucial role, not only in clinical decision making, but also in the assessment of prognosis.
- Open Access
- 14 September 2023
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 65 (1) , 165
Debating the Future of Nuclear Medicine: The Greek Experience
- 14 September 2023
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 65 (1) , 165
Open AccessDebating the Future of Nuclear Medicine: The Greek Experience
- Open Access
Automated Analysis vs. Expert Reading in Nuclear Cardiology: Correlations with the Angiographic Score
Background and Objectives: Myocardial perfusion imaging (MPI) has an important role in the non-invasive investigation of coronary artery disease. The interpretation of MPI studies is mainly based on the visual evaluation of the reconstructed images, while automated quantitation methods may add useful data for each patient. However, little evidence is currently available regarding the actual incremental clinical diagnostic performance of automated MPI analysis. In the present study, we aimed to assess the correlation between automated measurements of Summed Stress Score (SSS), Summed Rest Score (SRS) and Summed Difference Score (SDS), with the corresponding expert reading values, using coronary angiography as the gold standard. Materials and Methods: The study was conducted at the Nuclear Medicine Laboratory of the University Hospital of Larissa, Larissa, Greece, οver an one-year period (January 2019–January 2020). 306 patients, with known or suspected coronary artery disease, were enrolled in the study. Each participant underwent a coronary angiography, prior to or after the scintigraphic study (within a three-month period). Either symptom-limited treadmill test, or pharmacologic testing using adenosine or regadenoson, was performed in all participants, and the scintigraphic studies were carried out using technetium 99m (99mTc) tetrofosmin (one-day stress/rest protocol). Coronary angiographies were scored according to a 4-point scoring system (angiographic score; O: normal study, 1: one-vessel disease, 2: two-vessel disease, 3: three-vessel disease). Moreover, automated measurements of SSS, SRS and SDS were derived by three widely available software packages (Emory Cardiac Toolbox, Myovation, Quantitative Perfusion SPECT). Results: Interclass Correlation Coefficients of SSS, SRS and SDS between expert reading and software packages were moderate to excellent. Visually defined SSS, SRS and SDS were significantly correlated with the corresponding results of all software packages. However, visually defined SSS, SRS and SDS were more strongly correlated with the angiographic score, indicating a better performance of expert reading when compared to automated analysis. Conclusions: Based on our results, visual evaluation continues to have a crucial role for the interpretation of MPI images. Software packages can provide automated measurements of several parameters, particularly contributing to the investigation of cases with ambiguous scintigraphic findings.
Open AccessAutomated Analysis vs. Expert Reading in Nuclear Cardiology: Correlations with the Angiographic Score
Background and Objectives: Myocardial perfusion imaging (MPI) has an important role in the non-invasive investigation of coronary artery disease. The interpretation of MPI studies is mainly based on the visual evaluation of the reconstructed images, while automated quantitation methods may add useful data for each patient. However, little evidence is currently available regarding the actual incremental clinical diagnostic performance of automated MPI analysis. In the present study, we aimed to assess the correlation between automated measurements of Summed Stress Score (SSS), Summed Rest Score (SRS) and Summed Difference Score (SDS), with the corresponding expert reading values, using coronary angiography as the gold standard. Materials and Methods: The study was conducted at the Nuclear Medicine Laboratory of the University Hospital of Larissa, Larissa, Greece, οver an one-year period (January 2019–January 2020). 306 patients, with known or suspected coronary artery disease, were enrolled in the study. Each participant underwent a coronary angiography, prior to or after the scintigraphic study (within a three-month period). Either symptom-limited treadmill test, or pharmacologic testing using adenosine or regadenoson, was performed in all participants, and the scintigraphic studies were carried out using technetium 99m (99mTc) tetrofosmin (one-day stress/rest protocol). Coronary angiographies were scored according to a 4-point scoring system (angiographic score; O: normal study, 1: one-vessel disease, 2: two-vessel disease, 3: three-vessel disease). Moreover, automated measurements of SSS, SRS and SDS were derived by three widely available software packages (Emory Cardiac Toolbox, Myovation, Quantitative Perfusion SPECT). Results: Interclass Correlation Coefficients of SSS, SRS and SDS between expert reading and software packages were moderate to excellent. Visually defined SSS, SRS and SDS were significantly correlated with the corresponding results of all software packages. However, visually defined SSS, SRS and SDS were more strongly correlated with the angiographic score, indicating a better performance of expert reading when compared to automated analysis. Conclusions: Based on our results, visual evaluation continues to have a crucial role for the interpretation of MPI images. Software packages can provide automated measurements of several parameters, particularly contributing to the investigation of cases with ambiguous scintigraphic findings.
- Open Access
- 4 May 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (5) , 1136
Anosognosia in Dementia: Evaluation of Perfusion Correlates Using 99mTc-HMPAO SPECT and Automated Brodmann Areas Analysis
(1) Background: Considerable inconsistency exists regarding the neural substrates of anosognosia in dementia in previous neuroimaging studies. The purpose of this study was the evaluation of anosognosia perfusion correlates across various types of dementia using automated Brodmann areas (BAs) analysis and comparison with a database of normal subjects. (2) Methods: We studied 72 patients: 32 with Alzheimer’s disease, 26 with frontotemporal dementia—FTD (12 behavioral FTD, 9 semantic FTD, 5 Progressive Non-Fluent Aphasia), 11 with corticobasal syndrome, and 3 with progressive supranuclear palsy. Addenbrook’s Cognitive Examination—Revised (ACE-R) mean(±SD) was 55.6(±22.8). For anosognosia measurement, the Anosognosia Questionnaire—Dementia was used. Total anosognosia score mean(±SD) was 22.1(±17.9), cognitive anosognosia score mean(±SD) was 18.1(±15.1) and behavioral–mood anosognosia score mean(±SD) was 3.3(±4.7). (3) Results: Higher anosognosia total score was associated with hypoperfusion in the inferior temporal, anterior cingulate, and inferior frontal cortices of the right hemisphere (BAs 20R, 24R, 32R, 45R). Higher anosognosia cognitive score was correlated with hypoperfusion in the left middle and anterior temporal cortices, and right dorsal anterior cingulate cortex (BAs 21L, 22L, 32R). No association was found with behavioral–mood anosognosia. (4) Conclusions: Automated analysis of brain perfusion Single Photon Emission Computed Tomography could be useful for the investigation of anosognosia neural correlates in dementia.
- 4 May 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (5) , 1136
Open AccessAnosognosia in Dementia: Evaluation of Perfusion Correlates Using 99mTc-HMPAO SPECT and Automated Brodmann Areas Analysis
(1) Background: Considerable inconsistency exists regarding the neural substrates of anosognosia in dementia in previous neuroimaging studies. The purpose of this study was the evaluation of anosognosia perfusion correlates across various types of dementia using automated Brodmann areas (BAs) analysis and comparison with a database of normal subjects. (2) Methods: We studied 72 patients: 32 with Alzheimer’s disease, 26 with frontotemporal dementia—FTD (12 behavioral FTD, 9 semantic FTD, 5 Progressive Non-Fluent Aphasia), 11 with corticobasal syndrome, and 3 with progressive supranuclear palsy. Addenbrook’s Cognitive Examination—Revised (ACE-R) mean(±SD) was 55.6(±22.8). For anosognosia measurement, the Anosognosia Questionnaire—Dementia was used. Total anosognosia score mean(±SD) was 22.1(±17.9), cognitive anosognosia score mean(±SD) was 18.1(±15.1) and behavioral–mood anosognosia score mean(±SD) was 3.3(±4.7). (3) Results: Higher anosognosia total score was associated with hypoperfusion in the inferior temporal, anterior cingulate, and inferior frontal cortices of the right hemisphere (BAs 20R, 24R, 32R, 45R). Higher anosognosia cognitive score was correlated with hypoperfusion in the left middle and anterior temporal cortices, and right dorsal anterior cingulate cortex (BAs 21L, 22L, 32R). No association was found with behavioral–mood anosognosia. (4) Conclusions: Automated analysis of brain perfusion Single Photon Emission Computed Tomography could be useful for the investigation of anosognosia neural correlates in dementia.